IRE1 depletion downregulates multiple cell cycle proteins in synchronized cells. by Iratxe Zuazo-Gaztelu (21071939)

Binary classification task performance. by Thierry Jean (20691795)

Ordinal regression task performance. by Thierry Jean (20691795)

IRE1 depletion downregulates multiple cell cycle proteins in synchronized cells. by Iratxe Zuazo-Gaztelu (21071939)

Growth of certain cancer cell lines requires IRE1 but not its enzymatic activity. by Iratxe Zuazo-Gaztelu (21071939)

Endogenous IRE1 protein can localize to the nuclear envelope. by Iratxe Zuazo-Gaztelu (21071939)

IRE1 depletion induces cell cycle arrest independently of apoptosis. by Iratxe Zuazo-Gaztelu (21071939)

Growth of certain cancer cell lines requires IRE1 but not its enzymatic activity. by Iratxe Zuazo-Gaztelu (21071939)

Comparison of the shadow index of blindfolded compound eyes with wild-type gravid mosquitoes. by Si Yu Zhao (19544793)

2D and 3D AFM micrographs of fabricated samples (a) 5LZCM (b) 10LZCM (c) 15LZCM. by Md. Abu Daud (21485629)

Primary antibodies used for immunoblot analysis. by Iratxe Zuazo-Gaztelu (21071939)

“…IRE1 silencing led to activation of TP53 and CDKN1A/p21 in conjunction with increased DNA damage and chromosome instability, while decreasing heterochromatin as well as DNA and histone H3K9me3 methylation. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Determinants of childbirth in private HF among women who had a live birth one year before the survey, NDHS 2022. by Resham B. Khatri (10949429)

Principal Coordinate Analysis (PCoA) based on (A) Unweighted UniFrac, (B) Weighted UniFrac, (C) Bray-Curtis dissimilarity, and (D) Jaccard similarity. by Manal Ali Ahmad (16868808)

Pyrazole-Infused Metal Complexes: Anticancer Activity, DNA Cleavage, and Biophysical Insights into DNA/BSA Interactions by Tankadhar Behera (22267115)

“…Further, the use of reactive oxygen species (ROS) scavengers, such as hydroxyl radical scavenger, singlet oxygen scavenger, and superoxide scavenger, resulted in a significant decrease in the DNA cleavage efficiency. …”

Colored Gold Ions Enabled High-Transparent and Low-Haze Cellulose Films with Excellent Flame-Retardant and UV to Blue Light-Blocking Performance by Qiu Fu (10830823)

“…Quite encouragingly, the incorporation of Au³⁺ facilitates films in achieving desirable flame retardancy, evidenced by a significant increase in the limiting oxygen index from 19.2% to 39.2%. …”